BIOMED Adiponectin Reagent
– for the precise determination of total adiponectin
BIOMED Adiponectin Reagent is designed for the quantitative, immunoturbidimetric in vitro determination of adiponectin in human serum and plasma using clinical chemistry analyzers (e.g. Beckman AU Systems, Roche Cobas Systems, Siemens Advia Systems).
Performance features
- Lower detection limit: < 0,5 µg/mL
- No high-dose hook effect up to 150 µg/mL
- Measuring range: linear from 5 – 40 µg/mL
- Specificity: recovery versus target values
< ± 0.5 µg/mL for the range < 5 µg/mL
< ± 10 % for the range 5 – 40 µg/mL
Precision in the series
Comparison of control material in two concentration ranges (Low / High) in 10 replicates each on the Roche Cobas c501 instrument.
Table 1 Results of the precision study in the Adiponectin Reagent series.
Linearity
Measurement of 10 dilutions of one concentration level on the Roche Cobas c501 device.
Figure 1 Linear correlation between mean values of measured values and theoretical target values Adiponectin Reagent.
Device comparison with a commercially available Adiponectin ELISA and BIOMED Adiponectin Reagent.
In a comparative measurement with BIOMED Adiponectin on a Hit 917 and an Adiponectin ELISA, a correlation coefficient of > 0.98 was obtained between the two measurements.
Background
Adiponectin is a protein hormone and adipokine involved in various metabolic processes, including the regulation of glucose levels and fatty acid oxidation. It is secreted by adipocytes and by the placenta and has various functions:
- Inhibition of gluconeogenesis
- Stimulation of beta-oxidation
- Increase of insulin sensitivity
In addition, adiponectin has a vasoprotective and anti-atherosclerotic effect.
Dysregulation of adiponectin appears to have a strong influence on the development of the metabolic syndrome. Low adiponectin levels have been found to be associated with the development of obesity, type 2 diabetes, and coronary heart disease (CHD).
References
- L. Thomas: Labor und Diagnose, 2016, e-Version
- S. Stojanović, M. Deijanin Ilić et al: The significance of adiponectin as a biomarker in metabolic syndrome and/or coronary artery disease, Vojnosanit Pregl, 2015 Sep;72(9):779-84.
- Shanshan Li, Hyun Joon Shin et al: Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis, JAMA 2009 Jul 8;302(2):179-88.